John Gustofson
Direktor/Vorstandsmitglied bei Disarm Therapeutics, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Rajesh Devraj | M | - |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | 8 Jahre |
| Marc Dunoyer | M | 71 | 11 Jahre | |
| Jeffrey D Milbrandt | M | - |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | - |
| Zaven Kaprielian | M | - |
Endlyz Therapeutics, Inc.
 Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | - |
| Charles Kunsch | M | - |
AbbVie Ventures LLC
 AbbVie Ventures LLC Investment ManagersFinance AbbVie Ventures LLC (AbbVie Ventures) is a venture capital firm, a subsidiary of AbbVie, Inc. founded in 2009. The firm is headquartered in North Chicago, Illinois.
Endlyz Therapeutics, Inc.
Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | 11 Jahre |
| Pascal Soriot | M | 64 | 12 Jahre | |
| Tom Engber | M | - |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | 6 Jahre |
| Raul Krauss | M | - |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | 8 Jahre |
| Christian Schubert | M | - |
AbbVie Ventures LLC
AbbVie Ventures LLC Investment ManagersFinance AbbVie Ventures LLC (AbbVie Ventures) is a venture capital firm, a subsidiary of AbbVie, Inc. founded in 2009. The firm is headquartered in North Chicago, Illinois. | 2 Jahre |
| Jasmina Marjanovic | F | - |
AbbVie Ventures LLC
AbbVie Ventures LLC Investment ManagersFinance AbbVie Ventures LLC (AbbVie Ventures) is a venture capital firm, a subsidiary of AbbVie, Inc. founded in 2009. The firm is headquartered in North Chicago, Illinois. | 3 Jahre |
| Josie Afolabi | F | - | 14 Jahre | |
| Thomas Engber | M | - |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | - |
| Damian Crowther | M | - |
Endlyz Therapeutics, Inc.
Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | - |
| Kimi Iguchi | F | 61 |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | 6 Jahre |
| Tim Edwards | M | - |
Endlyz Therapeutics, Inc.
Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | - |
| Jean George | F | 66 |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | - |
| Susan Mary Galbraith | M | - | 14 Jahre | |
| Michael A. Eruzione | M | 69 |
Boston University
| 29 Jahre |
| Alfred Sandrock | M | 67 |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | - |
| Jonathan Behr | M | - |
Endlyz Therapeutics, Inc.
Endlyz Therapeutics, Inc. BiotechnologyHealth Technology Endlyz Therapeutics, Inc. is an American company that operates in the biotechnology industry. | - |
| James T. Stamas | M | 91 |
Boston University
| 29 Jahre |
| Danjuma Quarless | M | - |
AbbVie Ventures LLC
AbbVie Ventures LLC Investment ManagersFinance AbbVie Ventures LLC (AbbVie Ventures) is a venture capital firm, a subsidiary of AbbVie, Inc. founded in 2009. The firm is headquartered in North Chicago, Illinois. | 2 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ahmed Hamdy | M | 59 | - | |
| Julie Brown | F | 62 | 14 Jahre | |
| Abdulatif Al-Seif | M | 45 |
Boston University
| 9 Jahre |
| Leif Valdemar Johansson | M | 73 | 11 Jahre | |
| David Brennan | M | 70 | 13 Jahre | |
| Georges Gemayel | M | 63 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 1 Jahre |
| Shriti Vadera | F | 62 | 7 Jahre | |
| Geneviéve B. Berger | M | 69 | 9 Jahre | |
| Matthew Robert Renna | M | - |
Boston University
| 6 Jahre |
| Briggs Morrison | M | 65 | 3 Jahre | |
| Donald Bruce Burlington | M | 75 | 7 Jahre | |
| Thomas J. Phair | M | - |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 Jahre |
| Ayesha Bharmal | F | - | 5 Jahre | |
| Menelas Pangalos | M | 57 | 13 Jahre | |
| James Ward-Lilley | M | 59 | 1 Jahre | |
| Ben McMillan | M | 45 |
Boston University
| 4 Jahre |
| Minalkumar Patel | M | 52 |
Boston University
| 7 Jahre |
| Chris Lagan | M | - |
Boston University
| 3 Jahre |
| Ran Zhang | M | 56 |
Boston University
| 4 Jahre |
| Reem Haitham Jamil Goussous | F | 52 |
Boston University
| 6 Jahre |
| Andrew M. Jacobson | M | - |
Boston University
| 3 Jahre |
| Suzanne Hendrix | M | - |
Boston University
| 4 Jahre |
| Sheldon Berkle | M | 78 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 3 Jahre |
| Louis Schweitzer | M | 80 | 8 Jahre | |
| Edward Yee Ng | M | - |
Boston University
| 2 Jahre |
| Ryan Lee Langdon | M | 51 |
Miami University
| 5 Jahre |
| Michele Hooper | F | 72 | 9 Jahre | |
| Bruce A. Leicher | M | 68 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | 2 Jahre |
| Graham Chipchase | M | 61 | 9 Jahre | |
| David D. Pendergast | M | 76 |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | - |
| Vincent Fang | M | - |
Boston University
| 3 Jahre |
| Alexander Ramlie | M | 49 |
Boston University
| 1 Jahre |
| Sarah Menkes Henry | F | - |
Boston University
| 1 Jahre |
| Danielle H. Ferry | M | - |
Boston University
| 4 Jahre |
| Brian Herr | M | 47 |
Boston University
| 4 Jahre |
| Abdullah Alawardi | M | - |
Boston University
| 3 Jahre |
| Stephen Spanos | M | 61 |
Boston University
| 2 Jahre |
| Selene G. Parekh | M | - |
Boston University
| 3 Jahre |
| David Schwartz | M | 48 |
Boston University
| 4 Jahre |
| Oliver Austria | M | - |
Boston University
| 4 Jahre |
| Steven J. Wietrecki | M | - |
Boston University
| 2 Jahre |
| Alexandra Askandar | F | 52 |
Boston University
| 2 Jahre |
| Paul Wang | M | - |
Boston University
| 4 Jahre |
| Sara Elizabeth Chanda | F | 54 |
Boston University
| 2 Jahre |
| Anthony A. Burdin | M | 50 |
Boston University
| 4 Jahre |
| Joseph Listengart | M | 55 |
Boston University
| 2 Jahre |
| Robert Rosen | M | 51 |
Boston University
| 4 Jahre |
| Xiang Ge Liu | M | 57 |
Boston University
| 2 Jahre |
| Sean Donoghue | M | - |
Boston University
| 4 Jahre |
| Julius Vizner | M | - |
Boston University
| 4 Jahre |
| Aaron W. Moore | M | - |
Boston University
| 3 Jahre |
| Henry Wang | M | - |
Boston University
| 4 Jahre |
| Michael George Ghazal | M | - |
Boston University
| 4 Jahre |
| John T. McKenna | M | - |
Boston University
| 3 Jahre |
| Mike Finnerty | M | - |
Boston University
| 2 Jahre |
| Parker A. Schweich | M | - |
Boston University
| 3 Jahre |
| Gaurav Malik | M | - |
Boston University
| 1 Jahre |
| David Kobuszewski | M | - |
Boston University
| 4 Jahre |
| Dean Evans | M | - |
Boston University
| 4 Jahre |
| Anna Sherbakova | F | - |
Boston University
| 3 Jahre |
| Mohammed Ismail Ali | M | - |
Boston University
| 4 Jahre |
| Rob Guiliano | M | - |
Boston University
| 2 Jahre |
| Miguel del Gallego | M | - |
Boston University
| 4 Jahre |
| Teresa Occhiolini | F | - |
Boston University
| 4 Jahre |
| King Sau Mak | M | 51 |
Boston University
| 4 Jahre |
| Len Dolan | M | - |
Boston University
| 2 Jahre |
| Kevin Hom | M | - |
Boston University
| 4 Jahre |
| Nikole Kiralis | F | - |
Boston University
| 4 Jahre |
| Brian M. Garvey | M | - |
Boston University
| 2 Jahre |
| Stephen L. Simmons | M | - |
Boston University
| 4 Jahre |
| Joshua P. Eaton | M | - |
Boston University
| 3 Jahre |
| Mousa Awni Mousa Al-Saket | M | 50 |
Boston University
| 4 Jahre |
| Olga Tatar | F | - |
Boston University
| 4 Jahre |
| Michael Thomas Whitney | M | - |
Boston University
| 2 Jahre |
| Shai Greenwald | M | - |
Boston University
| 2 Jahre |
| Leonardo Arthur Po | M | 46 |
Boston University
| 4 Jahre |
| Mike J. Callahan | M | - |
Boston University
| 4 Jahre |
| Ellen Merete Hanetho | F | 60 |
Boston University
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Israel | 60 | 60,00% |
| Vereinigte Staaten | 22 | 22,00% |
| Vereinigtes Königreich | 18 | 18,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- John Gustofson
- Persönliches Netzwerk
